Market Place
Sourcing Support
Promontory Therapeutics `can`t hire fast enough` amid expansion
15 Jun 2022 //
FIERCEBIOTECH
Phosplatin Tx Adopts New Corporate Name as Promontory Therapeutics
05 May 2022 //
PRNEWSWIRE
Phosplatin doses first subject in Phase II thymic epithelial tumour trial
14 Apr 2022 //
CLINICALTRIALSARENA
Phosplatin Tx Begins Dosing in Phase 2 Trial of PT-112
13 Apr 2022 //
PRNEWSWIRE
Phosplatin Tx Appoints Lorenzo Galluzzi, PhD, to Scientific Advisory Board
24 Mar 2022 //
PRNEWSWIRE
Phosplatin Therapeutics Presents on PT-112 at the 2022 AACR
10 Mar 2022 //
PRNEWSWIRE
Phosplatin Therapeutics to Present at 2021 BIO Digital
10 Jun 2021 //
PRNEWSWIRE
Phosplatin Reports Ph1b Study Results of PT-112+avelumab at ASCO 2021
20 May 2021 //
PRNEWSWIRE
Phosplatin Therapeutics Presents Phase I Dose Escalation Data of PT-112
07 Dec 2020 //
PRNEWSWIRE
Phosplatin Announces Data Revealing Novel Mechanistic Attributes for PT-112
27 Oct 2020 //
PRNEWSWIRE
Phosplatin Announces Data Revealing Novel Mechanistic Attributes for PT-112
26 Oct 2020 //
PRNEWSWIRE
Phosplatin Therapeutics Doses First Patient in Phase 2 Study of PT-112
23 Oct 2020 //
PRNEWSWIRE
Phosplatin Therapeutics Announces Presentation of Research into PT-112
20 Oct 2020 //
BIOSPACE
Phosplatin Therapeutics Announces Presentation of Research into PT-112
20 Oct 2020 //
PRNEWSWIRE
Phosplatin Therapeutics Announces Results from PhI Study of PT-112 Plus Avelumab
18 Sep 2020 //
BIOSPACE
Phosplatin Therapeutics Announces Presentation of Phase 1b Combination Study
03 Sep 2020 //
PHARMIWEB
Phosplatin Therapeutic Announces Oral Presentation of Phase 1b Combination Study
02 Sep 2020 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.